Recombinant Human Coagulation FVIII · Hematology Recombinant human coagulation factor VIII replaces deficient or dysfunctional Factor VIII to restore the intrinsic coagulation pathway and enable normal blood clot formation.
Phase 3 pipeline
Placebos+chemo · Oncology A combination therapy pairing chemotherapy with placebo control to evaluate the efficacy of the chemotherapy agent in a Phase 3 clinical trial.
Rituximab plus CHOP · Oncology Rituximab targets CD20 on B cells, while CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is a chemotherapy regimen.
SCT-I10A+chemo · Oncology SCT-I10A+chemo combines a novel immunotherapy with chemotherapy to enhance the immune response against cancer cells while directly attacking them with chemotherapeutic agents.
SCT400 plus CHOP · Oncology SCT400 is a small molecule inhibitor of the BCL-2 family, while CHOP is a combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone.
SCT510A · Oncology SCT510A is a genetically modified allogeneic natural killer cell therapy designed to enhance anti-tumor immunity.
SCT630 SCT630 is a stem cell therapy that aims to regenerate or replace damaged tissue through cellular transplantation.
SCTB14 · Oncology SCTB14 is a small molecule targeting the CD47/SIRPα axis.
SCTC21C · Oncology SCTC21C is a chimeric antigen receptor T-cell (CAR-T) therapy engineered to target and eliminate cancer cells expressing specific tumor-associated antigens.
SCTV01E · Oncology SCTV01E is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.